Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Update

<< Previous

Bullboard Posts

Next >>

Comment by Goaweighon Feb 26, 2021 10:56am

114 Views

Post# 32670713

RE:RE:RE:Update

It is a bit odd that we haven't completed the AH merger yet, the owner is sitting in the office next door and the issue of bringing the IP home certainly can't be a new concept.
It's the only loose end that I know of and although it may be viewed by some as just housekeeping sometimes you just can't progress until you've got these issues resolved.
Getting a bit ridiculous actually.

dwventure wrote: I just asked him if we will get any update soon on IND and Intellectual property ownership after the recent bought deal. I guess he figured I am a little concerned about the share price drop lately.
He sounded pretty confident IMHO

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario